The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Targeting cellular metabolism to improve cancer therapeutics
Open accessAbstract
The metabolic properties of cancer cells diverge significantly from those of normal cells. Energy production in cancer cells is abnormally dependent on aerobic glycolysis. In addition to the dependency on glycolysis, cancer cells have other atypical metabolic characteristics such as increased fatty acid synthesis and increased rates of glutamine metabolism. Emerging evidence shows that many features characteristic to cancer cells, such as dysregulated Warburg-like glucose metabolism, fatty acid synthesis and glutaminolysis are linked to therapeutic resistance in cancer treatment. Therefore, targeting cellular metabolism may improve the response to cancer therapeutics and the combination of chemotherapeutic drugs with cellular metabolism inhibitors may represent a promising strategy to overcome drug resistance in cancer therapy. Recently, several review articles have summarized the anticancer targets in the metabolic pathways and metabolic inhibitor-induced cell death pathways, however, the dysregulated metabolism in therapeutic resistance, which is a highly clinical relevant area in cancer metabolism research, has not been specifically addressed. From this unique angle, this review article will discuss the relationship between dysregulated cellular metabolism and cancer drug resistance and how targeting of metabolic enzymes, such as glucose transporters, hexokinase, pyruvate kinase M2, lactate dehydrogenase A, pyruvate dehydrogenase kinase, fatty acid synthase and glutaminase can enhance the efficacy of common therapeutic agents or overcome resistance to chemotherapy or radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia
Zhang, H., Bosch-Marce, M., Shimoda, L. A., Tan, Y. S., Baek, J. H., Wesley, J. B., Gonzalez, F. J., & Semenza, G. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800102200 · Cited by 1,601
RetractedUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,679
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
On Respiratory Impairment in Cancer Cells
Warburg, O. (1956) · Science · doi:10.1126/science.124.3215.269 · Cited by 3,468
(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
Cited by
Advances in Copper Complexes as Anticancer Agents
Santini, C., Pellei, M., Gandin, V., Porchia, M., Tisato, F., & Marzano, C. (2014) · Chemical Reviews · doi:10.1021/cr400135x · Cited by 1,790
Tumor glycolysis as a target for cancer therapy: progress and prospects
Ganapathy-Kanniappan, S., & Geschwind, J.-F. H. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-152 · Cited by 1,395
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
“Substantial work has sought to target increased glycolysis including efforts to inhibit lactate production and excretion (Doherty and Cleveland, 2013; Hamanaka and Chandel, 2012; Hay, 2016; Pelicano et al., 2006; Zhao et al., 2013).”
BackgroundRegulation of pyruvate metabolism and human disease
Gray, L. R., Tompkins, S. C., & Taylor, E. B. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1539-2 · Cited by 947
Li, S.-Y., Cheng, H., Xie, B.-R., Qiu, W.-X., Zeng, J.-Y., Li, C.-X., Wan, S.-S., Zhang, L., Liu, W.-L., & Zhang, X.-Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b02533 · Cited by 780
The anti-cancer effect of quercetin: molecular implications in cancer metabolism
Reyes-Farias, M., & Carrasco-Pozo, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133177 · Cited by 689
Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation
Schiliro, C., & Firestein, B. L. (2021) · Cells · doi:10.3390/cells10051056 · Cited by 615
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 591
Lee, S. Y., Jeong, E. K., Ju, M. K., Jeon, H. M., Kim, M. Y., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0577-4 · Cited by 578
The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor
Valvona, C. J., Fillmore, H. L., Nunn, P. B., & Pilkington, G. J. (2016) · Brain Pathology · doi:10.1111/bpa.12299 · Cited by 567
Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer
Qu, Q., Zeng, F., Liu, X., Wang, Q. J., & Deng, F. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.132 · Cited by 545
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Roberts, D. J., & Miyamoto, S. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.173 · Cited by 504
Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension
Bertero, T., Oldham, W. M., Cottrill, K. A., Pisano, S., Vanderpool, R. R., Yu, Q., Zhao, J., Tai, Y., Tang, Y., Zhang, Y.-Y., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86387 · Cited by 439
Supramolecular cancer nanotheranostics
Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411
Cancer cell metabolism: implications for therapeutic targets
Jang, M., Kim, S. S., & Lee, J. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.85 · Cited by 397
3D microtumors in vitro supported by perfused vascular networks
Sobrino, A., Phan, D. T. T., Datta, R., Wang, X., Hachey, S. J., Romero-López, M., Gratton, E., Lee, A. P., George, S. C., & Hughes, C. C. W. (2016) · Scientific Reports · doi:10.1038/srep31589 · Cited by 387
Chen, W.-H., Luo, G.-F., Lei, Q., Hong, S., Qiu, W.-X., Liu, L.-H., Cheng, S.-X., & Zhang, X.-Z. (2017) · ACS Nano · doi:10.1021/acsnano.6b06658 · Cited by 367
Stimuli-sensitive nanopreparations for combination cancer therapy
Jhaveri, A., Deshpande, P., & Torchilin, V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.002 · Cited by 334
Inorganic nanoparticles for biomedicine: where materials scientists meet medical research
Giner-Casares, J. J., Henriksen-Lacey, M., Coronado-Puchau, M., & Liz-Marzán, L. M. (2016) · Materials Today · doi:10.1016/j.mattod.2015.07.004 · Cited by 317
Walsh, A. J., Cook, R. S., Sanders, M. E., Aurisicchio, L., Ciliberto, G., Arteaga, C. L., & Skala, M. C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0663 · Cited by 312
Tan, Y., Li, J., Zhao, G., Huang, K.-C., Cardenas, H., Wang, Y., Matei, D., & Cheng, J.-X. (2022) · Nature Communications · doi:10.1038/s41467-022-32101-w · Cited by 306
Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review)
Yang, L., Xie, H.-J., Li, Y.-Y., Wang, X., Liu, X.-X., & Mai, J. (2022) · Oncology Reports · doi:10.3892/or.2022.8293 · Cited by 304
Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia
Peng, F., Wang, J.-H., Fan, W.-J., Meng, Y.-T., Li, M.-M., Li, T.-T., Cui, B., Wang, H.-F., Zhao, Y., An, F., et al. (2018) · Oncogene · doi:10.1038/onc.2017.368 · Cited by 303
Self-citationA distinct glucose metabolism signature of acute myeloid leukemia with prognostic value
Chen, W.-L., Wang, J.-H., Zhao, A.-H., Xu, X., Wang, Y.-H., Chen, T.-L., Li, J.-M., Mi, J.-Q., Zhu, Y.-M., Liu, Y.-F., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554204 · Cited by 302
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
You, M., Xie, Z., Zhang, N., Zhang, Y., Xiao, D., Liu, S., Zhuang, W., Li, L., & Tao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01442-3 · Cited by 292
Agnihotri, S., & Zadeh, G. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov125 · Cited by 291
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Xiang, Y., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 287
Yu, L., Lu, M., Jia, D., Ma, J., Ben-Jacob, E., Levine, H., Kaipparettu, B. A., & Onuchic, J. N. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2074 · Cited by 272
Ciavardelli, D., Rossi, C., Barcaroli, D., Volpe, S., Consalvo, A., Zucchelli, M., De Cola, A., Scavo, E., Carollo, R., D'Agostino, D., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.285 · Cited by 269
Liao, M., Yao, D., Wu, L., Luo, C., Wang, Z., Zhang, J., & Liu, B. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.003 · Cited by 261
Tedeschi, P. M., Markert, E. K., Gounder, M., Lin, H., Dvorzhinski, D., Dolfi, S. C., Chan, L. L.-Y., Qiu, J., DiPaola, R. S., Hirshfield, K. M., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.393 · Cited by 260
Caveolin-1 in the regulation of cell metabolism: a cancer perspective
Nwosu, Z. C., Ebert, M. P., Dooley, S., & Meyer, C. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0558-7 · Cited by 256
Agostini, M., & Knight, R. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1825 · Cited by 254
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Grasso, C., Jansen, G., & Giovannetti, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.026 · Cited by 253
Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach
Chen, L., & Cui, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922830 · Cited by 184
The mechanism of Warburg effect-induced chemoresistance in cancer
Liu, C., Jin, Y., & Fan, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698023 · Cited by 177
Bianchi, G., Martella, R., Ravera, S., Marini, C., Capitanio, S., Orengo, A., Emionite, L., Lavarello, C., Amaro, A., Petretto, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3688 · Cited by 173
Rational Cell Culture Optimization Enhances Experimental Reproducibility in Cancer Cells
Wright Muelas, M., Ortega, F., Breitling, R., Bendtsen, C., & Westerhoff, H. V. (2018) · Scientific Reports · doi:10.1038/s41598-018-21050-4 · Cited by 160
Zaytseva, Y. Y., Harris, J. W., Mitov, M. I., Kim, J. T., Butterfield, D. A., Lee, E. Y., Weiss, H. L., Gao, T., & Evers, B. M. (2015) · Oncotarget · doi:10.18632/oncotarget.3783 · Cited by 153
Sappington, D. R., Siegel, E. R., Hiatt, G., Desai, A., Penney, R. B., Jamshidi-Parsian, A., Griffin, R. J., & Boysen, G. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.01.021 · Cited by 143
“Mechanistic studies in tissue culture and animal models suggest glutamine utilization and glutathione synthesis are important in cancer promotion and progression [16,24,36,38,42].”
BackgroundGlutaminolysis and autophagy in cancer
Villar, V. H., Merhi, F., Djavaheri-Mergny, M., & Durán, R. V. (2015) · Autophagy · doi:10.1080/15548627.2015.1053680 · Cited by 143
Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies
Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B. (2022) · Cancers · doi:10.3390/cancers14194568 · Cited by 144
Romero-López, M., Trinh, A. L., Sobrino, A., Hatch, M. M. S., Keating, M. T., Fimbres, C., Lewis, D. E., Gershon, P. D., Botvinick, E. L., Digman, M., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.034 · Cited by 125
Napoleão, A., Fernandes, L., Miranda, C., & Marum, A. P. (2021) · Nutrients · doi:10.3390/nu13041302 · Cited by 103
O’Neill, S., Porter, R. K., McNamee, N., Martinez, V. G., & O’Driscoll, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-39789-9 · Cited by 93
Liu, B., Jia, Y., Cao, Y., Wu, S., Jiang, H., Sun, X., Ma, J., Yin, X., Mao, A., & Shang, M. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000445633 · Cited by 75
Monti, D. M., Ferraro, G., Petruk, G., Maiore, L., Pane, F., Amoresano, A., Cinellu, M. A., & Merlino, A. (2017) · Dalton Transactions · doi:10.1039/c7dt02370g · Cited by 49
Osinalde, N., Mitxelena, J., Sánchez-Quiles, V., Akimov, V., Aloria, K., Arizmendi, J. M., Zubiaga, A. M., Blagoev, B., & Kratchmarova, I. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.057158 · Cited by 48
The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities
Cordani, M., Michetti, F., Zarrabi, A., Zarepour, A., Rumio, C., Strippoli, R., & Marcucci, F. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101076 · Cited by 40
Glutamine deprivation counteracts hypoxia-induced chemoresistance
Wappler, J., Arts, M., Röth, A., Heeren, R. M. A., Peter Neumann, U., Olde Damink, S. W., Soons, Z., & Cramer, T. (2020) · Neoplasia · doi:10.1016/j.neo.2019.10.004 · Cited by 34
Shining a light on metabolic vulnerabilities in non-small cell lung cancer
Dowling, C. M., Zhang, H., Chonghaile, T. N., & Wong, K.-K. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188462 · Cited by 26
Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition
Hendrick, E., Peixoto, P., Blomme, A., Polese, C., Matheus, N., Cimino, J., Frère, A., Mouithys-Mickalad, A., Serteyn, D., Bettendorff, L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.103 · Cited by 18
Thabet, N. M., Abdel-Rafei, M. K., El-Sayyad, G. S., Elkodous, M. A., Shaaban, A., Du, Y.-C., Rashed, L. A., & Askar, M. A. (2022) · Cancer Nanotechnology · doi:10.1186/s12645-022-00122-1 · Cited by 7
Metadata
- Authors
- Zhao, Y., Butler, E. B., & Tan, M.
- Venue
- Cell Death & Disease
- Published
- 2013-03-07
- Volume
- 4
- Issue
- 3
- Pages
- e532-e532
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2037679360
- Cited by
- 989
- References
- 122
- FWCI
- 33.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.